Tacrolimus (FK506) suppresses TNF-α-induced CCL2 (MCP-1) and CXCL10 (IP-10) expression via the inhibition of p38 MAP kinase activation in human colonic myofibroblasts

International Journal of Molecular Medicine

Volumn 30, Issue 5, 2012, Pages 1152-1158

  Aomatsu, Tomoki ^a,b   Imaeda, Hirotsugu ^a   Takahashi, Kenichiro ^a   Fujimoto, Takehide ^a   Kasumi, Eiji ^a   Yoden, Atsushi ^b   Tamai, Hiroshi ^b   Fujiyama, Yoshihide ^a   Andoh, Akira ^a  

^a SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^b OSAKA MEDICAL COLLEGE   (Japan)

Author keywords

Chemokine; Inflammatory bowel disease; Tumor necrosis factor

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 MORPHOLINO 8 PHENYLCHROMONE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 6; INTERLEUKIN 8; MITOGEN ACTIVATED PROTEIN KINASE P38; MONOCYTE CHEMOTACTIC PROTEIN 1; STAT1 PROTEIN; TACROLIMUS; TUMOR NECROSIS FACTOR ALPHA;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CYTOKINE RESPONSE; ENTERITIS; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MYOFIBROBLAST; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; WESTERN BLOTTING;

CELLS, CULTURED; CHEMOKINE CCL2; CHEMOKINE CXCL10; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; GENE EXPRESSION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MYOFIBROBLASTS; NF-KAPPA B; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; TACROLIMUS; TRANSCRIPTIONAL ACTIVATION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84866631453     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2012.1094     Document Type: Article

References (48)

1. Podolsky DK: Inflammatory bowel disease. N Engl J Med 347: 417-429, 2002.
2. Mizoguchi A and Mizoguchi E: Inflammatory bowel disease, past, present and future: lessons from animal models. J Gastroenterol 43: 1-17, 2008. (Pubitemid 351324980)
3. Sartor RB: Mechanisms of disease: pathogenesis of Crohn's disease and ulcerative colitis. Nat Clin Pract Gastroenterol Hepatol 3: 390-407, 2006.
4. Kobori A, Yagi Y, Imaeda H, et al: Interleukin-33 expression is specifically enhanced in inflamed mucosa of ulcerative colitis. J Gastroenterol 45: 999-1007, 2010.
5. Mayer L: Evolving paradigms in the pathogenesis of IBD. J Gastroenterol 45: 9-16, 2010.
6. Faubion WA Jr, Loftus EV Jr, Harmsen WS, Zinsmeister AR and Sandborn WJ: The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 121: 255-260, 2001. (Pubitemid 32729372)
7. Taylor KM and Irving PM: Optimization of conventional therapy in patients with IBD. Nat Rev Gastroenterol Hepatol 8: 646-656, 2011.
8. McSharry K, Dalzell AM, Leiper K and El-Matary W: Systematic review: the role of tacrolimus in the management of Crohn's disease. Aliment Pharmacol Ther 34: 1282-1294, 2011.
9. Naganuma M, Fujii T and Watanabe M: The use of traditional and newer calcineurin inhibitors in inflammatory bowel disease. J Gastroenterol 46: 129-137, 2011.
10. Benson A, Barrett T, Sparberg M and Buchman AL: Efficacy and safety of tacrolimus in refractory ulcerative colitis and Crohn's disease: a single-center experience. Inflamm Bowel Dis 14: 7-12, 2008. (Pubitemid 351196862)
11. Ogata H, Matsui T, Nakamura M, et al: A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis. Gut 55: 1255-1262, 2006. (Pubitemid 44277355)
12. Ogata H, Kato J, Hirai F, et al: Double-blind, placebo-controlled trial of oral tacrolimus (FK506) in the management of hospitalized patients with steroid-refractory ulcerative colitis. Inflamm Bowel Dis 18: 803-808, 2012.
13. Yamamoto S, Nakase H, Matsuura M, Masuda S, Inui K and Chiba T: Tacrolimus therapy as an alternative to thiopurines for maintaining remission in patients with refractory ulcerative colitis. J Clin Gastroenterol 45: 526-530, 2011.
14. Yamamoto S, Nakase H, Mikami S, et al: Long-term effect of tacrolimus therapy in patients with refractory ulcerative colitis. Aliment Pharmacol Ther 28: 589-597, 2008.
15. Busuttil RW and Lake JR: Role of tacrolimus in the evolution of liver transplantation. Transplantation 77: S44-S51, 2004. (Pubitemid 38668459)
16. Vincenti F: A decade of progress in kidney transplantation. Transplantation 77: S52-S61, 2004.
17. Rusnak F and Mertz P: Calcineurin: form and function. Physiological Rev 80: 1483-1521, 2000.
18. Liao W, Lin JX and Leonard WJ: IL-2 family cytokines: new insights into the complex roles of IL-2 as a broad regulator of T helper cell differentiation. Curr Opin Immunol 23: 598-604, 2011.
19. Lazarevic V and Glimcher LH: T-bet in disease. Nat Immunol 12: 597-606, 2011.
20. Singh UP, Venkataraman C, Singh R and Lillard JW Jr: CXCR3 axis: role in inflammatory bowel disease and its therapeutic implication. Endocr Metab Immune Disord Drug Targets 7: 111-123, 2007. (Pubitemid 46969859)
21. + T lymphocytes are preferentially recruited to the ileum in Crohn's disease. Gut 53: 1287-1294, 2004.
22. Grip O and Janciauskiene S: Atorvastatin reduces plasma levels of chemokine (CXCL10) in patients with Crohn's disease. PLoS One 4: e5263, 2009.
23. Banks C, Bateman A, Payne R, Johnson P and Sheron N: Chemokine expression in IBD. Mucosal chemokine expression is unselectively increased in both ulcerative colitis and Crohn's disease. J Pathol 199: 28-35, 2003. (Pubitemid 36054726)
24. Zhang HH, Song K, Rabin RL, et al: CCR2 identifies a stable population of human effector memory CD4+ T cells equipped for rapid recall response. J Immunol 185: 6646-6663, 2010.
25. Charo IF and Peters W: Chemokine receptor 2 (CCR2) in atherosclerosis, infectious diseases, and regulation of T-cell polarization. Microcirculation 10: 259-264, 2003. (Pubitemid 39004253)
26. Kim YG, Kamada N, Shaw MH, et al: The Nod2 sensor promotes intestinal pathogen eradication via the chemokine CCL2-dependent recruitment of inflammatory monocytes. Immunity 34: 769-780, 2011.
27. Liu M, Guo S, Hibbert JM, et al: CXCL10/IP-10 in infectious diseases pathogenesis and potential therapeutic implications. Cytokine Growth Factor Rev 22: 121-130, 2011.
28. Danese S, Colombel JF, Reinisch W and Rutgeerts PJ: Review article: infliximab for Crohn's disease treatment - shifting therapeutic strategies after 10 years of clinical experience. Aliment Pharmacol Ther 33: 857-869, 2011.
29. Hanauer SB, Kornbluth AA, Messick J, Rubin DT, Sandborn WJ and Sands BE: Clinical scenarios in IBD: optimizing the use of conventional and biologic agents. Inflamm Bowel Dis 16: S1-S11, 2010.
30. Allez M, Vermeire S, Mozziconacci N, et al: The efficacy and safety of a third anti-TNF monoclonal antibody in Crohn's disease after failure of two other anti-TNF antibodies. Aliment Pharmacol Ther 31: 92-101, 2010.
31. Mahida YR, Beltinger J, Makh S, et al: Adult human colonic subepithelial myofibroblasts express extracellular matrix proteins and cyclooxygenase-1 and -2. Am J Physiol 273: G1341-G1348, 1997.
32. Okuno T, Andoh A, Bamba S, et al: Interleukin-1beta and tumor necrosis factor-alpha induce chemokine and matrix metalloproteinase gene expression in human colonic subepithelial myofibroblasts. Scand J Gastroenterol 37: 317-324, 2002. (Pubitemid 34194818)
33. Andoh A, Takaya H, Saotome T, et al: Cytokine regulation of chemokine (IL-8, MCP-1, and RANTES) gene expression in human pancreatic periacinar myofibroblasts. Gastroenterology 119: 211-219, 2000. (Pubitemid 30452595)
34. Shimada M, Andoh A, Hata K, et al: IL-6 secretion by human pancreatic periacinar myofibroblasts in response to inflammatory mediators. J Immunol 168: 861-868, 2002. (Pubitemid 34049589)
35. Inatomi O, Andoh A, Kitamura K, Yasui H, Zhang Z and Fujiyama Y: Butyrate blocks interferon-gamma-inducible protein-10 release in human intestinal subepithelial myofibroblasts. J Gastroenterol 40: 483-489, 2005. (Pubitemid 40823283)
36. Qi XF, Kim DH, Yoon YS, et al: Essential involvement of crosstalk between IFN-gamma and TNF-alpha in CXCL10 production in human THP-1 monocytes. J Cell Physiol 220: 690-697, 2009.
37. Wu C, Ohmori Y, Bandyopadhyay S, Sen G and Hamilton T: Interferon-stimulated response element and NF kappa B sites cooperate to regulate double-stranded RNA-induced transcription of the IP-10 gene. J Interferon Res 14: 357-363, 1994.
38. Shultz DB, Rani MR, Fuller JD, Ransohoff RM and Stark GR: Roles of IKK-beta, IRF1, and p65 in the activation of chemokine genes by interferon-gamma. J Interferon Cytokine Res 29: 817-824, 2009.
39. Wong CK, Wang CB, Ip WK, Tian YP and Lam CW: Role of p38 MAPK and NF-κB for chemokine release in coculture of human eosinophils and bronchial epithelial cells. Clin Exp Immunol 139: 90-100, 2005. (Pubitemid 40066133)
40. Hata K, Andoh A, Shimada M, et al: IL-17 stimulates inflammatory responses via NF-kappaB and MAP kinase pathways in human colonic myofibroblasts. Am J Physiol Gastrointest Liver Physiol 282: G1035-G1044, 2002. (Pubitemid 34651610)
41. Reinecker HC, Loh EY, Ringler DJ, Mehta A, Rombeau JL and MacDermott RP: Monocyte-chemoattractant protein 1 gene expression in intestinal epithelial cells and inflammatory bowel disease mucosa. Gastroenterology 108: 40-50, 1995.
42. Uguccioni M, Gionchetti P, Robbiani DF, et al: Increased expression of IP-10, IL-8, MCP-1, and MCP-3 in ulcerative colitis. Am J Pathol 155: 331-336, 1999. (Pubitemid 29370382)
43. Manousou P, Kolios G, Valatas V, et al: Increased expression of chemokine receptor CCR3 and its ligands in ulcerative colitis: the role of colonic epithelial cells in in vitro studies. Clin Exp Immunol 162: 337-347, 2010.
44. Herfarth H, Pollok-Kopp B, Goke M, Press A and Oppermann M: Polymorphism of CC chemokine receptors CCR2 and CCR5 in Crohn's disease. Immunol Lett 77: 113-117, 2001. (Pubitemid 32480127)
45. Herfarth H, Goke M, Hellerbrand C, et al: Polymorphism of monocyte chemoattractant protein 1 in Crohn's disease. Int J Colorectal Dis 18: 401-405, 2003. (Pubitemid 37062730)
46. Egan CE, Craven MD, Leng J, Mack M, Simpson KW and Denkers EY: CCR2-dependent intraepithelial lymphocytes mediate inflammatory gut pathology during Toxoplasma gondii infection. Mucosal Immunol 2: 527-535, 2009.
47. Singh UP, Singh S, Taub DD and Lillard JW Jr: Inhibition of IFN-gamma-inducible protein-10 abrogates colitis in IL-10-/- mice. J Immunol 171: 1401-1406, 2003. (Pubitemid 36900073)
48. Yoshino T, Nakase H, Honzawa Y, et al: Immunosuppressive effects of tacrolimus on macrophages ameliorate experimental colitis. Inflamm Bowel Dis 16: 2022-2033, 2010.